Sfoglia per AUTORE
ROSELLI M
Collezione AO Cuneo

  

Items : 6

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. in Scientific reports / Sci Rep. 2021 Jul 2;11(1):13770. doi: 10.1038/s41598-021-92774-z.

2021
AO Cuneo

Vici P; Ciliberto G; Sanguineti G; Di Leo A; De Maria R; Daralioti T; Sperduti I; Perracchio L; di Benedetto A; Del Medico P; Roselli M; Vaccaro A; Garufi C; Cazzaniga M; Lorusso V; Russo A; Pistelli M; Giotta F; Meattini I; Garrone O; Paris I; Sarobba G; Veltri E; Corsi D; D'Ostilio N; Grassadonia A; Valerio MR; Mirabelli R; Fabbri MA; et alii...

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. in Journal of cellular physiology / J Cell Physiol. 2020 Nov;235(11):7900-7910. doi: 10.1002/jcp.29445. Epub 2020 Jan 15.

2020
AO Cuneo

Vici P; Giordano A; Barba M; Mazzotta M; Sperduti I; Ciliberto G; Villa A; Risi E; De Maria R; Del Medico P; Generali D; Meattini I; Livi L; Garrone O; Baldini E; Zamagni C; Pistelli M; Cannita K; Valerio MR; Berardi R; Russo A; Ricciardi G; Adamo V; Ficorella C; Roselli M; Lorusso V; Landucci E; Paris I; Giotta F; et alii...

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. in Journal of experimental & clinical cancer research : CR / J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3.

2020
AO Cuneo

Roselli M; Del Medico P; Cazzaniga M; Garufi C; Sarobba G; Giotta F; Paris I; Garrone O; Veltri E; Corsi D; D'Ostilio N; Fabbri MA; Russo A; Mirabelli R; Valerio MR; Marchetti P; Tomao S; Marinelli D; Mazzotta M; Barchiesi G; Zamagni C; Tonini G; Adamo V; Michelotti A; Moscetti L; Bria E; Cassano A; La Verde N; Generali D; et alii...

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. in International journal of cancer / Int J Cancer. 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583. Epub 2019 Aug 7.

2020
AO Cuneo

Vici P; Di Leo A; Barba M; Villa A; Ciliberto G; Sperduti I; De Maria R; Risi E; Generali D; De Tursi M; Sarobba G; Del Medico P; Meattini I; Desideri I; Livi L; Baldini E; Di Cocco B; Foglietta J; Greco F; Zamagni C; Garrone O; D'Ostilio N; Sini V; Cannita K; Adamo V; Ricciardi GRR; Fiorio E; Pistelli M; Russo A; et alii...

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. in The Lancet. Oncology / Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9.

2020
AOU Città della Salute di Torino
AO Cuneo

Fenocchio E; Mammoliti S; Cupini S; Roselli M; Mambrini A; Ritorto G; Clavarezza M; Carlomagno C; Di Donato S; Ronzoni M; Masi G; Tomasello G; Antonuzzo L; Corallo S; Cordio S; Moretto R; Buonadonna A; Granetto C; Murgioni S; Zaniboni A; Aprile G; Grande R; Marmorino F; Passardi A; Santini D; Tamburini E; Latiano TP; Bordonaro R; Pietrantonio F; et alii...

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer in Annals of Oncology

2014
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 2

Bajetta E; Floriani I; Di Bartolomeo M; Labianca R; Falcone A; Di Costanzo F; Comella G; Amadori D; Pinto C; Carlomagno C; Nitti D; Daniele B; Mini E; Poli D; Santoro A; Mosconi S; Casaretti R; Boni C; Pinotti G; Bidoli P; Landi L; Rosati G; Ravaioli A; Cantore M; Di Fabio F; Aitini E; Marchet A; Rulli E; Cropalato Di Tullio M; et alii...